FUTRUE Neurosciences

FUTRUE Neurosciences develops brain-computer interfaces (BCIs). The website describes work in four areas: decoding speech from neural activity, controlling prostheses and stimulating neural circuits for movement, targeted nerve stimulation for touch, and neurostimulation for vision.

The website names patients with ALS, stroke, spinal cord injury, amputation, glaucoma or macular degeneration as the people these technologies are meant to help. It does not describe a revenue model, pricing or commercial customers. The company presents itself as part of the FUTRUE Group, which it says has previously brought healthcare products to market, including a medical product for irritable bowel syndrome and an opioid substitute for chronic pain.

The website lists two managing directors, Bastian Baasch and Dr.-Ing. Max Dingler, and names Dr. med. Clemens Fischer as founder and shareholder of the FUTRUE Group, which he founded in 2007. The company's stated goal is to develop the world's leading generation of BCIs by 2030. Its eight open roles are in Gräfelfing near Munich and cover BCI development, neural software engineering, microfabrication and manufacturing, and analog/mixed-signal IC design.

Product: Brain-computer interface systems for restoring speech, motor function, tactile sensation and vision, under clinical development.